Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP
Menopausal symptoms can impair the life of women at the peak of their career and family life. At the present time, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormone therapy is the fear of physicians to do more harm to patients than good. Caution is especially important when it comes to women with concurrent diseases. Moreover, it should be recognized that there is a shortage of high-quality research on the safety of MHT for underlying chronic non-infectious diseases and common comorbidities. The presented consensus analyzed all currently available data from clinical trials of various designs and created a set of criteria for the appropriateness of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, physicians of various specialties who advise menopausal women will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real-life practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Kardiologiia - 63(2023), 10 vom: 08. Nov., Seite 9-28 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Shlyakhto, E V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.11.2023 Date Revised 20.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18087/cardio.2023.10.n2561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364624337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364624337 | ||
| 003 | DE-627 | ||
| 005 | 20231226095823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.18087/cardio.2023.10.n2561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364624337 | ||
| 035 | |a (NLM)37970852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Shlyakhto, E V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Menopausal symptoms can impair the life of women at the peak of their career and family life. At the present time, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormone therapy is the fear of physicians to do more harm to patients than good. Caution is especially important when it comes to women with concurrent diseases. Moreover, it should be recognized that there is a shortage of high-quality research on the safety of MHT for underlying chronic non-infectious diseases and common comorbidities. The presented consensus analyzed all currently available data from clinical trials of various designs and created a set of criteria for the appropriateness of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, physicians of various specialties who advise menopausal women will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real-life practice | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Sukhikh, G T |e verfasserin |4 aut | |
| 700 | 1 | |a Serov, V N |e verfasserin |4 aut | |
| 700 | 1 | |a Dedov, I I |e verfasserin |4 aut | |
| 700 | 1 | |a Arutyunov, G P |e verfasserin |4 aut | |
| 700 | 1 | |a Suchkov, I A |e verfasserin |4 aut | |
| 700 | 1 | |a Orlova, Ya A |e verfasserin |4 aut | |
| 700 | 1 | |a Andreeva, E N |e verfasserin |4 aut | |
| 700 | 1 | |a Yureneva, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Yavelov, I S |e verfasserin |4 aut | |
| 700 | 1 | |a Yarmolinskaya, M I |e verfasserin |4 aut | |
| 700 | 1 | |a Villevalde, S V |e verfasserin |4 aut | |
| 700 | 1 | |a Grigoryan, O R |e verfasserin |4 aut | |
| 700 | 1 | |a Dudinskaya, E N |e verfasserin |4 aut | |
| 700 | 1 | |a Ilyukhin, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Koziolova, N A |e verfasserin |4 aut | |
| 700 | 1 | |a Sergienko, I V |e verfasserin |4 aut | |
| 700 | 1 | |a Smetnik, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Tapilskaya, N I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kardiologiia |d 1961 |g 63(2023), 10 vom: 08. Nov., Seite 9-28 |w (DE-627)NLM000007153 |x 0022-9040 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:10 |g day:08 |g month:11 |g pages:9-28 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18087/cardio.2023.10.n2561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 10 |b 08 |c 11 |h 9-28 | ||